Immunoexpression and Mutation Status of BRAF V600E in Papillary Thyroid Carcinoma
Background: BRAF V600E mutation, with incidence rates ranging from 29% to 83% of papillary thyroid carcinoma (PTC), is the most common genetic mutation. Several methods have been used to detect this mutation but the determination of the rapid and easily available techniques is still needed. Thus, the aim was to describe the diagnostic performance of faster BRAFV600E-specific immunohistochemical method (IHC), compared to the amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) technique.
Methods: The histologically proven, paraffin-embedded tissue blocks of 44 papillary thyroid carcinoma patients who attended the Otorhinolaryngology, Head and Neck Surgery Specialist Hospital, Yangon, were collected. Anti-BRAF V600E monoclonal antibody was used for the IHC of tissue sections. For ARMS-PCR, the BRAF V600E mutation was detected after DNA extraction, followed by genomic DNA amplification using the QIAGEN Taq PCR Core kit.
Results: The mutation was found in 77.3% (34/44) and 75% (33/44) cases using IHC and ARMS-PCR, respectively. A total of 98% concordance was found between IHC and ARMS-PCR (43/44 tests). IHC results showed 100% (33/33) sensitivity, 91% (10/11) specificity, 97% (33/44) positive predictive values), and 100% (10/10) negative predictive values.
Conclusion: The results demonstrated that BRAF V600E IHC possesses the appropriate sensitivity and specificity for diagnostic use. This method could be considered a reliable preliminary screening technique in addition to a molecular approach for BRAF V600E mutation detection in papillary thyroid carcinoma patients on a routine basis.
2. Martinuzzi C, Pastorino L, Andreotti V, Garuti A, Minuto M, Fiocca R, et al. A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer. Endocrine. 2016;53(3):672-80.
3. Scheffel RS, de Cristo AP, Romitti M, Vargas CVF, Ceolin L, Zanella AB, et al. The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma. Arch Endocrinol Metab. 2021;64(6):751-7.
4. Al-Salam S, Sharma C, Afandi B, Al Dahmani K, Al-Zahrani AS, Al Shamsi A, et al. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates. PLoS One. 2020;15(4):e0231341.
5. Daliri M, Abbaszadegan MR, Bahar MM, Arabi A, Yadollahi M, Ghafari A, et al. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study. Endocr Res. 2014;39(4):189-93.
6. Szymonek M, Kowalik A, Kopczyński J, Gąsior-Perczak D, Pałyga I, Walczyk A, et al. Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma. Oncotarget. 2017;8(43):74897.
7. Laha D, Nilubol N, Boufraqech M. New therapies for advanced thyroid Cancer. Frontiers in Endocrinology. 2020;11(82):1-9.
8. Tran TV, Dang KX, Pham QH, Nguyen UD, Trinh NTT, Hoang LV, et al. Evaluation of the expression levels of BRAF(V600E) mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay. BMC Cancer. 2020;20(1):368.
9. Parker KG, White MG, Cipriani NA. Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis. Head Neck Pathol. 2020;14(4):1067-79.
10. Tennakoon T, Rushdhi M, Ranasinghe A, Dassanayake RS. Values of molecular markers in the differential diagnosis of thyroid abnormalities. J Cancer Res Clin Oncol. 2017;143(6):913-31.
11. Zhu X, Luo Y, Bai Q, Lu Y, Lu Y, Wu L, et al. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma. Exp Mol Pathol. 2016;100(1):236-41.
12. Lasota J, Kowalik A, Wasag B, Wang Z-F, Felisiak-Golabek A, Coates T, et al. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach. The American journal of surgical pathology. 2014;38(9):1235-41.
13. Paja Fano M, Ugalde Olano A, Fuertes Thomas E, Oleaga Alday A. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction. Endocrinología, Diabetes y Nutrición (English ed). 2017;64(2):75-81.
14. Than O, Than MM, Zin L, Thyn NMM. Immunoexpression of Mutated BRAF V600E Protein in Papillary Thyroid Carcinoma. Asian Oncology Research Journal. 2023;6(1):1-14.
15. Kang SH, Pyo JY, Yang SW, Hong SW. Detection of BRAF V600E mutation with thyroid tissue using pyrosequencing: comparison with PNA-clamping and real-time PCR. Am J Clin Pathol. 2013;139(6):759-64.
16. Mahdieh N, Rabbani B. An overview of mutation detection methods in genetic disorders. Iranian journal of pediatrics. 2013;23(4):375.
17. Medrano RF, de Oliveira CA. Guidelines for the tetra-primer ARMS-PCR technique development. Mol Biotechnol. 2014;56(7):599-608.
18. Rosman N, Nawawi HM, Al-Khateeb A, Chua YA, Chua AL. Development of an Optimized Tetra-Amplification Refractory Mutation System PCR for Detection of 12 Pathogenic Familial Hypercholesterolemia Variants in the Asian Population. J Mol Diagn. 2022;24(2):120-30.
19. Zabala AS, Gomez MEV, Alvarez MF, Siewert S. Tetra Primer ARMS PCR Optimization to Detect Single Nucleotide Polymorphism of the KLF14 Gene. OALib. 2017;04(12):1-14.
20. Kristiani E, Hardjolukito ES, Harahap AS, Makes B. BRAF V600E Immunoexpression in Papillary Thyroid Carcinoma and Its Association with Prognostic Factors and Histopathologic Variant. Medicinus. 2021;8(1):12-21.
21. Rashid FA, Tabassum S, Khan MS, Ansari HR, Asif M, Sheikh AK, et al. VE1 immunohistochemistry is an adjunct tool for detection of BRAF(V600E) mutation: Validation in thyroid cancer patients. J Clin Lab Anal. 2021;35(2):e23628.
22. Ge J, Wang J, Wang H, Jiang X, Liao Q, Gong Q, et al. The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer. J Cancer. 2020;11(4):932-9.
23. Kure S, Ishino K, Kudo M, Wada R, Saito M, Nagaoka R, et al. Incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma: a single-institution experience. J Int Med Res. 2019;47(11):5560-72.
24. Bandoh N, Akahane T, Goto T, Kono M, Ichikawa H, Sawada T, et al. Targeted next‑generation sequencing of cancer‑related genes in thyroid carcinoma: A single institution's experience. Oncology Letters. 2018;16(6):7278-86.
25. Yoon JH, Han K, Lee E, Lee J, Kim E-K, Moon HJ, et al. Radiomics in predicting mutation status for thyroid cancer: A preliminary study using radiomics features for predicting BRAFV600E mutations in papillary thyroid carcinoma. PloS one. 2020;15(2):e0228968.
26. Yan C, Huang M, Li X, Wang T, Ling R. Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma. Endocrine connections. 2019;8(7):988.
27. Espiritu GAM, Malana JT, Dumasis AJGV, Ang DC. High preponderance of BRAF V600E mutation in papillary thyroid carcinoma among Filipinos: a clinicopathologic study. Journal of Global Oncology. 2019;5:1-6.
28. Nasirden A, Saito T, Fukumura Y, Hara K, Akaike K, Kurisaki-Arakawa A, et al. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation. Virchows Archiv. 2016;469:687-96.
29. Chai YJ, Kim Sj, Kim SC, Koo DH, Min HS, Lee KE, et al. BRAF mutation in follicular variant of papillary thyroid carcinoma is associated with unfavourable clinicopathological characteristics and malignant features on ultrasonography. Clinical endocrinology. 2014;81(3):432-9.
30. Geng J, Wang H, Liu Y, Tai J, Jin Y, Zhang J, et al. Correlation between BRAF V600E mutation and clinicopathological features in pediatric papillary thyroid carcinoma. Science China Life Sciences. 2017;60:729-38.
31. Than MM. BRAF(V600E) Mutation in Papillary Thyroid Carcinoma. Yangon, Republic of the Union of Myanmar.: University of Medicine. 2017
32. McKelvie PA, Chan F, Yu Y, Waring P, Gresshoff I, Farrell S, et al. The prognostic significance of the BRAFV600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry. Pathology. 2013;45(7):637-44.
33. Na JI, Kim JH, Kim HJ, Kim HK, Moon KS, Lee JS, et al. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. Virchows Arch. 2015;467(2):155-68.
34. Zhu X, Luo Y, Bai Q, Lu Y, Lu Y, Wu L, et al. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma. Experimental and molecular pathology. 2016;100(1):236-41.
35. Zhang X, Wang L, Wang J, Zhao H, Wu J, Liu S, et al. Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma. Exp Mol Pathol. 2018;105(1):153-9.
36. Rashid FA, Tabassum S, Khan MS, Ansari HR, Asif M, Sheikh AK, et al. VE1 immunohistochemistry is an adjunct tool for detection of BRAFV600E mutation: Validation in thyroid cancer patients. Journal of Clinical Laboratory Analysis. 2021;35(2):e23628.
37. Zagzag J, Pollack A, Dultz L, Dhar S, Ogilvie JB, Heller KS, et al. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery. 2013;154(6):1199-204; discussion 204-5.
38. Sun J, Zhang J, Lu J, Gao J, Lu T, Ren X, et al. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma. International journal of clinical and experimental pathology. 2015;8(11):15072.
39. Choden S, Keelawat S, Jung CK, Bychkov A. VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAF(V600E) Mutation in Papillary Thyroid Cancer. Cancers (Basel). 2020;12(3).
Copyright (c) 2023 Ohnmar Than, Dr. Mie Mie Than, Dr. Le՝ Shwe Zin, Dr. Nyo Me May Thyn
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.